Compare CMMB & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMMB | MYND |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 19.2M |
| IPO Year | 2023 | 2017 |
| Metric | CMMB | MYND |
|---|---|---|
| Price | $2.85 | $0.39 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 98.2K | 43.7K |
| Earning Date | 05-21-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $67.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.28 |
| 52 Week High | $3.55 | $1.15 |
| Indicator | CMMB | MYND |
|---|---|---|
| Relative Strength Index (RSI) | 84.13 | 49.54 |
| Support Level | $1.47 | $0.30 |
| Resistance Level | $2.86 | $0.49 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 87.54 | 27.97 |
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.